Ipamorelin
Ipamorelin
A selective growth hormone secretagogue with a clean stimulation profile and minimal side effects at research doses.
Ipamorelin is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Ipamorelin is a pentapeptide (5 amino acids) and selective growth hormone releasing peptide (GHRP). It stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the pituitary gland.
What distinguishes Ipamorelin from other GHRPs is its selectivity — it produces a more targeted GH pulse without significantly elevating cortisol or prolactin, which are common concerns with older GHRPs like GHRP-6.
What research shows
- Selective GH pulse stimulation without cortisol or prolactin elevation at research doses
- Increased IGF-1 levels in animal models
- Improved bone density in some animal studies
- Potential fat oxidation effects via GH elevation
- Synergistic GH release when paired with CJC-1295
What remains unknown
- Optimal long-term dosing protocols in humans
- Full safety profile with extended human use
- Comparative GH release versus other secretagogues in humans specifically
Administration basics
Common use cases
GH optimization, body composition, recovery, longevity protocols. Almost always stacked with CJC-1295.
Half-life
~2 hours.
Administration
Subcutaneous injection. Typically dosed 2–3x daily or before sleep.
Source this compound
Looking for Ipamorelin?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Research studies have used 200–300mcg per injection
- Community protocols commonly report 200–300mcg per injection, typically 1–3x daily, often before sleep and/or training
Administration routes studied
Typical protocol duration
Research studies have run 8–12 weeks. Community protocols commonly report 3–6 month cycles with breaks.
Common stacking protocols
- Ipamorelin + CJC-1295 — the most widely studied and reported GHRP/GHRH combination
- Ipamorelin + BPC-157 or TB-500 — combined in recovery-focused protocols
Contraindications & combinations to avoid
- Active cancer or personal/family history of certain cancers — GH elevation may be a concern; consult an oncologist
- Diabetes or insulin resistance — GH peptides can affect insulin sensitivity; blood glucose monitoring is advisable
- Should not be combined with other GHRPs such as GHRP-2 or GHRP-6 — redundant mechanism
- Pituitary disorders — consult an endocrinologist
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Ipamorelin and what to avoid.
Track your Ipamorelin protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Ipamorelin page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.